Adaptive Biotechnologies Corp. reported first‑quarter 2026 results that surpassed expectations across the board. Revenue rose 35% year‑over‑year to $70.9 million, a $9.1 million (14.6%) beat over the $61.8 million consensus estimate. Earnings per share were a loss of $0.13, improving from a $0.16 loss forecast and representing a $0.03 beat. Net loss narrowed to $20.0 million from $29.8 million in Q1 2025, while adjusted EBITDA improved to a $2.5 million loss from a $12.7 million loss a year earlier. Sequencing gross margin climbed eight percentage points to 70%, reflecting stronger pricing power and operational efficiencies.
The company’s core Minimal Residual Disease (MRD) segment drove the majority of the revenue growth, generating $67.1 million—up 53% from the prior year—thanks to accelerated adoption in both clinical testing and drug‑development collaborations. In contrast, the Immune Medicine segment contracted 57% to $3.8 million, a decline attributed to the timing of sample receipts and processing and the absence of Genentech Agreement revenue. The company also recognized $9 million of milestone revenue in Q1, a one‑time contribution that will not recur in 2026.
Operating expenses increased 10% to $90.1 million, driven by higher research and development and sales‑and‑marketing spend. Despite the expense rise, the company’s cost‑control program helped narrow the net loss and improve adjusted EBITDA. Cash, cash equivalents and marketable securities stood at $237.2 million as of March 31, 2026, providing a robust liquidity cushion.
Management raised its full‑year MRD revenue guidance to $260 million–$270 million, up from the previous $255 million–$265 million range, and maintained operating‑expense guidance at $350 million–$360 million. The company reiterated its target of achieving positive adjusted EBITDA and free cash flow in 2026, and it now expects volumes to grow at least 35% in 2026 with potential upside.
"We delivered strong first quarter results based on accelerating adoption of MRD across both clinical testing and drug development. Our performance reinforces our market leadership position and the differentiated value of our platform. With disciplined execution and multiple growth drivers in place, we are well positioned to sustain our growth trajectory and create long‑term value," said CEO Chad Robins. "We are raising our full‑year MRD revenue guidance to a range of $260 million to $270 million," added CFO Kyle Piskel. "This range includes $9 million of MRD milestone revenue, which was recognized in the first quarter, and we do not anticipate additional milestone revenue for the remainder of 2026," Piskel added. "We now expect volumes to grow to at least 35% in 2026 with potential for upside," Robins continued. "Importantly, we remain on track to achieve positive adjusted EBITDA and positive free cash flow for the full company in 2026," Robins concluded. "Our Q1 results reflect the accelerating momentum of our MRD business and our disciplined execution, which are driving significant revenue growth and margin expansion," he added. "Pharma is lumpy quarter to quarter," Piskel noted.
Adaptive Biotechnologies’ results reinforce its position as a leader in the MRD testing market, with the clonoSEQ diagnostic test gaining broader clinical adoption and reimbursement coverage, including a recent Texas Medicaid policy inclusion. The company’s focus on scaling the MRD business, coupled with disciplined cost management, positions it to achieve profitability and free‑cash‑flow generation in 2026. Meanwhile, the decline in the Immune Medicine segment highlights ongoing challenges in that area, but the company’s strategic investments and partnership pipeline suggest a potential turnaround in the longer term. Overall, the earnings beat and raised guidance signal strong confidence in the company’s core business and a clear path toward sustainable growth.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.